XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 89.97

Change

+0.92 (+1.03)%

Market Cap

N/A

Volume

0.01B

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-12 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.21 (-0.14%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

-0.04 (-0.06%)

USD 2.66B
FXH First Trust Health Care AlphaD..

-0.73 (-0.68%)

USD 1.05B
XHE SPDR® S&P Health Care Equipme..

-1.13 (-1.23%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.20 (+0.90%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.39 (+1.23%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

-0.33 (-0.33%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.06 (+0.20%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+0.44 (+0.72%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.34 (+1.61%)

USD 6.89M

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

-0.03 (0%)

USD 0.06B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.10% 19% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.10% 19% F 29% F
Trailing 12 Months  
Capital Gain -1.28% 24% F 28% F
Dividend Return 0.14% 19% F 1% F
Total Return -1.14% 24% F 22% F
Trailing 5 Years  
Capital Gain -7.33% 19% F 41% F
Dividend Return 0.48% 26% F 2% F
Total Return -6.85% 19% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -2.88% 14% F 19% F
Dividend Return -2.80% 14% F 12% F
Total Return 0.07% 21% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 30.21% 19% F 35% F
Risk Adjusted Return -9.27% 14% F 15% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.